ZOFRAN®

(ondansetron hydrochloride)

Tablets

ZOFRAN® ODT™

(ondansetron)

Orally Disintegrating Tablets

ZOFRAN®

(ondansetron hydrochloride)

Oral Solution

DESCRIPTION: The active ingredient in ZOFRAN Tablets and ZOFRAN Oral Solution is ondansetron hydrochloride (HCl) as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT_3 receptor type. Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. It has the following structural formula:



The empirical formula is $C_{18}H_{19}N_3O \cdot HCl \cdot 2H_2O$, representing a molecular weight of 365.9.

Ondansetron HCl dihydrate is a white to off-white powder that is soluble in water and normal saline.

The active ingredient in ZOFRAN ODT Orally Disintegrating Tablets is ondansetron base, the racemic form of ondansetron, and a selective blocking agent of the serotonin 5-HT_3 receptor type. Chemically it is (±)1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one. It has the following structural formula:



The empirical formula is $C_{18}H_{19}N_3O$ representing a molecular weight of 293.4.

Each 4-mg ZOFRAN Tablet for oral administration contains ondansetron HCl dihydrate equivalent to 4 mg of ondansetron. Each 8-mg ZOFRAN Tablet for oral administration contains ondansetron HCl dihydrate equivalent to 8 mg of ondansetron. Each tablet also contains the inactive ingredients lactose, microcrystalline cellulose, pregelatinized starch, hydroxypropyl methylcellulose, magnesium stearate, titanium dioxide, iron oxide yellow (8-mg tablet only), and sodium benzoate (4-mg tablet only).

Each 4-mg ZOFRAN ODT Orally Disintegrating Tablet for oral administration contains 4 mg ondansetron base. Each 8-mg ZOFRAN ODT Orally Disintegrating Tablet for oral administration contains 8 mg ondansetron base. Each ZOFRAN ODT Tablet also contains the inactive ingredients aspartame, gelatin, mannitol, methylparaben sodium, propylparaben sodium, and strawberry flavor. ZOFRAN ODT Tablets are a freeze-dried, orally administered formulation of ondansetron which rapidly disintegrates on the tongue and does not require water to aid dissolution or swallowing.

Each 5 mL of ZOFRAN Oral Solution contains 5 mg of ondansetron HCl dihydrate equivalent to 4 mg of ondansetron. ZOFRAN Oral Solution contains the inactive ingredients citric acid anhydrous, purified water, sodium benzoate, sodium citrate, sorbitol, and strawberry flavor.

CLINICAL PHARMACOLOGY:

Pharmacodynamics: Ondansetron is a selective 5-HT_3 receptor antagonist. While its mechanism of action has not been fully characterized, ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT_3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether ondansetron's antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine. In humans, urinary 5-HIAA (5-hydroxyindoleacetic acid) excretion increases after cisplatin administration in parallel with the onset of emesis. The released serotonin may stimulate the vagal afferents through the 5-HT_3 receptors and initiate the vomiting reflex.

In animals, the emetic response to cisplatin can be prevented by pretreatment with an inhibitor of serotonin synthesis, bilateral abdominal vagotomy and greater splanchnic nerve section, or pretreatment with a serotonin 5-HT_3 receptor antagonist.

In normal volunteers, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time. Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers. Ondansetron has no effect on plasma prolactin concentrations.

Pharmacokinetics: Ondansetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered from the urine as the parent compound. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. Although some

nonconjugated metabolites have pharmacologic activity, these are not found in plasma concentrations likely to significantly contribute to the biological activity of ondansetron.

Oral ondansetron is well absorbed and undergoes limited first-pass metabolism. Following the administration of a single 8-mg ondansetron tablet to healthy, young, male volunteers and from pooled studies, the time to peak plasma ondansetron concentration is approximately 1.7 hours, the terminal elimination half-life is approximately 3 hours, and bioavailability is approximately 56%. Gender differences were shown in the disposition of ondansetron given as a single dose. The extent and rate of ondansetron's absorption is greater in women than men. Slower clearance in women, a smaller apparent volume of distribution (adjusted for weight), and higher absolute bioavailability resulted in higher plasma ondansetron levels. These higher plasma levels may in part be explained by differences in body weight between men and women. It is not known whether these gender-related differences were clinically important. More detailed pharmacokinetic information is contained in the following table taken from one study.

Pharmacokinetics in Normal Volunteers: Single 8-mg ZOFRAN Tablet Dose

Age-group (years)	Mean Weight (kg)	n	Peak Plasma Concentration (ng/mL)	Time of Peak Plasma Concentration (h)	Mean Elimination Half-life (h)	Systemic Plasma Clearance L/h/kg	Absolute Bioavail-ability
18-40 M	69.0	6	26.2	2.0	3.1	0.403	0.483
F	62.7	5	42.7	1.7	3.5	0.354	0.663
61-74 M	77.5	6	24.1	2.1	4.1	0.384	0.585
F	60.2	6	52.4	1.9	4.9	0.255	0.643
≥75 M	78.0	5	37.0	2.2	4.5	0.277	0.619
F	67.6	6	46.1	2.1	6.2	0.249	0.747

Four and 8-mg doses of either ZOFRAN Oral Solution or ZOFRAN ODT Orally Disintegrating Tablets are bioequivalent to corresponding dose of ZOFRAN Tablets and may be used interchangeably.

Both AUC and C_{max} more than double on increasing the tablet dose from 8 to 16 mg (123% and 118%, respectively). This may result from saturation of first-pass metabolism leading to greater oral bioavailability at 16 mg than 8 mg.

The administration of oral ondansetron with food increases significantly (about 17%) the extent of absorption of ondansetron. The peak plasma concentration and time to peak plasma concentration are not significantly affected. This change in the extent of absorption is not believed to be of any clinical relevance.

There was no significant effect of antacid administration on the pharmacokinetics of orally administered ondansetron.

Because ondansetron undergoes extensive metabolism, the modest reduction in clearance in the over-75 age-group was not unexpected. However, since there was a difference in neither safety nor efficacy between

patients over 65 years of age and those under 65 years of age, no adjustment in dosage is required in the elderly.

Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL. Circulating drug also distributes into erythrocytes.

CLINICAL TRIALS:

Chemotherapy-Induced Nausea and Vomiting: In one double-blind US study in 67 patients, ZOFRAN Tablets were significantly more effective than placebo in preventing vomiting induced by cyclophosphamide-based chemotherapy containing doxorubicin. Treatment response is based on the total number of emetic episodes over the 3-day study period. The results of this study are summarized below:

Emetic Episodes: Treatment Response

	Ondansetron 8-mg b.i.d. ZOFRAN Tablets*	Placebo	*P*-Value
Number of patients	33	34	
Treatment response			
0 Emetic episodes	20 (61%)	2 (6%)	<0.001
1-2 Emetic episodes	6 (18%)	8 (24%)	
More than 2 emetic episodes/withdrawn	7 (21%)	24 (71%)	<0.001
Median number of emetic episodes	0.0	Undefined†	
Median time to first emetic episode (h)	Undefined‡	6.5	

* The first dose was administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. An 8-mg ZOFRAN Tablet was administered twice a day for 2 days after completion of chemotherapy.

† Median undefined since at least 50% of the patients were withdrawn or had more than two emetic episodes.

‡ Median undefined since at least 50% of patients did not have any emetic episodes.

In one double-blind US study in 336 patients, ZOFRAN Tablets 8 mg administered twice a day were as effective as ZOFRAN Tablets 8 mg administered three times a day in preventing nausea and vomiting induced by cyclophosphamide-based chemotherapy containing either methotrexate or doxorubicin. Treatment response is based on the total number of emetic episodes over the 3-day study period. The results of this study are summarized below:

Emetic Episodes: Treatment Response

	Ondansetron	
	8-mg b.i.d. ZOFRAN Tablets*	8-mg t.i.d. ZOFRAN Tablets†
Number of patients	165	171
Treatment response		
0 Emetic episodes	101 (61%)	99 (58%)
1-2 Emetic episodes	16 (10%)	17 (10%)
More than 2 emetic episodes/withdrawn	48 (29%)	55 (32%)
Median number of emetic episodes	0.0	0.0
Median time to first emetic episode (h)	Undefined‡	Undefined‡
Median nausea scores (0-100)§	6	6

* The first dose was administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. An 8-mg ZOFRAN Tablet was administered twice a day for 2 days after completion of chemotherapy.
† The first dose was administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. An 8-mg ZOFRAN Tablet was administered three times a day for 2 days after completion of chemotherapy.
‡ Median undefined since at least 50% of patients did not have any emetic episodes.
§ Visual analog scale assessment: 0 = no nausea, 100 = nausea as bad as it can be.

Re-treatment: In uncontrolled trials, 148 patients receiving cyclophosphamide-based chemotherapy were re-treated with ZOFRAN Tablets 8 mg t.i.d. of oral ondansetron during subsequent chemotherapy for a total of 396 re-treatment courses. No emetic episodes occurred in 314 (79%) of the re-treatment courses, and only one to two emetic episodes occurred in 43 (11%) of the re-treatment courses.

Pediatric Studies: Three open-label, uncontrolled, foreign trials have been performed with 182 patients 4 to 18 years old with cancer who were given a variety of cisplatin or noncisplatin regimens. In these foreign trials, the initial dose of ZOFRAN® (ondansetron HCl) Injection ranged from 0.04 to 0.87 mg/kg for a total dose of 2.16 to 12 mg. This was followed by the administration of ZOFRAN Tablets ranging from 4 to 24 mg daily for 3 days. In these studies, 58% of the 170 evaluable patients had a complete response (no emetic episodes) on day 1. Two studies showed the response rates for patients less than 12 years of age who received ZOFRAN Tablets 4 mg three times a day to be similar to those in patients 12 to 18 years of age who received ZOFRAN Tablets 8 mg three times daily. Thus, prevention of emesis in these children was essentially the same as for patients older than 18 years of age. Overall, ZOFRAN Tablets were well tolerated in these pediatric patients.

Elderly Patients: One hundred thirty-seven (137) patients 65 years of age or older have received ZOFRAN Tablets. Prevention of emesis was similar to that in patients younger than 65 years of age and adverse reactions were not seen in increased frequency.

Radiation-Induced Nausea and Vomiting: ***Total Body Irradiation:*** In a randomized, double-blind study in 20 patients, ZOFRAN Tablets (8 mg given 1.5 hours before each fraction of radiotherapy for 4 days) were significantly more effective than placebo in preventing vomiting induced by total body irradiation. Total body irradiation consisted of 11 fractions (120 cGy per fraction) over 4 days for a total of 1,320 cGy. Patients received three fractions for 3 days, then two fractions on day 4.

Single High-Dose Fraction Radiotherapy: Ondansetron was significantly more effective than metoclopramide with respect to complete control of emesis (0 emetic episodes) in a double-blind trial in 105 patients receiving single high-dose radiotherapy (800 to 1,000 cGy) over an anterior or posterior field size of ≥80 cm^2 to the abdomen. Patients received the first dose of ZOFRAN Tablets (8 mg) or metoclopramide (10 mg) 1 to 2 hours before radiotherapy. If radiotherapy was given in the morning, two additional doses of study treatment were given (one tablet late afternoon and one tablet before bedtime). If radiotherapy was given in the afternoon, patients took only one further tablet that day before bedtime. Patients continued the oral medication on a t.i.d. basis for 3 days.

Daily Fractionated Radiotherapy: Ondansetron was significantly more effective than prochlorperazine with respect to complete control of emesis (0 emetic episodes) in a double-blind trial in 135 patients receiving a 1- to 4-week course of fractionated radiotherapy (180 cGy doses) over a field size of ≥100 cm^2 to the abdomen. Patients received the first dose of ZOFRAN Tablets (8 mg) or prochlorperazine (10 mg) 1 to 2 hours before the patient received the first daily radiotherapy fraction, with two subsequent doses on a t.i.d. basis. Patients continued the oral medication on a t.i.d. basis on each day of radiotherapy.

Postoperative Nausea and Vomiting: Surgical patients who received ondansetron 1 hour before the induction of general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil, sufentanil, morphine, or fentanyl; nitrous oxide; neuromuscular blockade: succinylcholine/curare or gallamine and/or vecuronium, pancuronium, or atracurium; and supplemental isoflurane or enflurane) were evaluated in two double-blind studies (one US study, one foreign) involving 865 patients. ZOFRAN Tablets (16 mg) were significantly more effective than placebo in preventing postoperative nausea and vomiting.

The study populations in all trials thus far consisted of women undergoing inpatient surgical procedures. No studies have been performed in males. No controlled clinical study comparing ZOFRAN Tablets to ZOFRAN Injection has been performed.

INDICATIONS AND USAGE:

1. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
2. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.
3. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ZOFRAN Tablets, ZOFRAN ODT Orally Disintegrating Tablets, and ZOFRAN Oral Solution are recommended even where the incidence of postoperative nausea and/or vomiting is low.

CONTRAINDICATIONS: ZOFRAN Tablets, ZOFRAN ODT Orally Disintegrating Tablets, and ZOFRAN Oral Solution are contraindicated for patients known to have hypersensitivity to the drug.

WARNINGS: Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT_3 receptor antagonists.

PRECAUTIONS: Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.

Information for Patients: ***Phenylketonurics:*** Phenylketonuric patients should be informed that ZOFRAN ODT Orally Disintegrating Tablets contain phenylalanine (a component of aspartame). Each 4-mg and 8-mg orally disintegrating tablet contains <0.03 mg phenylalanine.

Patients should be instructed not to remove ZOFRAN ODT Tablets from the blister until just prior to dosing. The tablet should not be pushed through the foil. With dry hands, the blister backing should be peeled completely off the blister. The tablet should be gently removed and immediately placed on the tongue to dissolve and be swallowed with the saliva. Peelable illustrated stickers are affixed to the product carton that can be provided with the prescription to ensure proper use and handling of the product.

Drug Interactions: Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. On the basis of available data, no dosage adjustment is recommended for patients on these drugs. Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.

Use in Surgical Patients: The coadministration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenic effects were not seen in 2-year studies in rats and mice with oral ondansetron doses up to 10 and 30 mg/kg per day, respectively. Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of ondansetron up to 15 mg/kg per day did not affect fertility or general reproductive performance of male and female rats.

Pregnancy: ***Teratogenic Effects: Pregnancy Category B:*** Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: Ondansetron is excreted in the breast milk of rats. It is not known whether ondansetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ondansetron is administered to a nursing woman.

Pediatric Use: Little information is available about dosage in children 4 years of age or younger (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION sections for use in children 4 to 18 years of age).

Use in Elderly Patients: Dosage adjustment is not needed in patients over the age of 65 (see CLINICAL PHARMACOLOGY). Prevention of nausea and vomiting in elderly patients was no different than in younger age-groups.

ADVERSE REACTIONS: The following have been reported as events in clinical trials or in the routine management of patients treated with ondansetron, the active ingredient of ZOFRAN. A causal relationship to therapy with ZOFRAN has been unclear in many cases.

Chemotherapy-Induced Nausea and Vomiting: The following adverse events have been reported in adults receiving either 8 mg of ZOFRAN Tablets two or three times a day for 3 days or placebo in four trials. These patients were receiving concurrent chemotherapy, primarily cyclophosphamide-based regimens.

Principal Adverse Events in US Trials: 3 Days of Therapy With ZOFRAN Tablets

Event	Ondansetron 8 mg b.i.d. n = 242	Ondansetron 8 mg t.i.d. n = 415	Placebo n = 262
Headache	58 (24%)	113 (27%)	34 (13%)
Malaise/fatigue	32 (13%)	37 (9%)	6 (2%)
Constipation	22 (9%)	26 (6%)	1 (<1%)
Diarrhea	15 (6%)	16 (4%)	10 (4%)
Dizziness	13 (5%)	18 (4%)	12 (5%)
Abdominal pain	3 (1%)	13 (3%)	1 (<1%)
Xerostomia	5 (2%)	6 (1%)	1 (<1%)
Weakness	0 (0%)	7 (2%)	1 (<1%)

Central Nervous System: There have been rare reports consistent with, but not diagnostic of, extrapyramidal reactions in patients receiving ondansetron.

Hepatic: In 723 patients receiving cyclophosphamide-based chemotherapy in US clinical trials, AST and/or ALT values have been reported to exceed twice the upper limit of normal in approximately 1% to 2% of patients receiving ZOFRAN Tablets. The increases were transient and did not appear to be related to dose or duration of therapy. On repeat exposure, similar transient elevations in transaminase values occurred in some courses, but symptomatic hepatic disease did not occur. The role of cancer chemotherapy in these biochemical changes cannot be clearly determined.

There have been reports of liver failure and death in patients with cancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. The etiology of the liver failure is unclear.

Integumentary: Rash has occurred in approximately 1% of patients receiving ondansetron.

Other: Rare cases of anaphylaxis, bronchospasm, tachycardia, angina (chest pain), hypokalemia, electrocardiographic alterations, vascular occlusive events, and grand mal seizures have been reported. Except for bronchospasm and anaphylaxis, the relationship to ZOFRAN was unclear.

Radiation-Induced Nausea and Vomiting: The adverse events reported in patients receiving ZOFRAN Tablets and concurrent radiotherapy were similar to those reported in patients receiving ZOFRAN Tablets and concurrent chemotherapy. The most frequently reported adverse events were headache, constipation, and diarrhea.

Postoperative Nausea and Vomiting: The following adverse events have been reported in ≥5% of patients receiving ZOFRAN Tablets at a dosage of 16 mg orally in clinical trials. With the exception of headache, rates of these events were not significantly different in the ondansetron and placebo groups. These patients were receiving multiple concomitant perioperative and postoperative medications.

Frequency of Adverse Events From Controlled Studies with ZOFRAN Tablets

Adverse Event	Ondansetron 16 mg (n = 550)	Placebo (n = 531)
Wound problem	152 (28%)	162 (31%)
Drowsiness/sedation	112 (20%)	122 (23%)
Headache	49 (9%)	27 (5%)
Hypoxia	48 (8%)	35 (7%)
Pyrexia	45 (8%)	34 (6%)
Dizziness	36 (7%)	34 (6%)
Gynecological disorder	36 (7%)	33 (6%)
Anxiety/agitation	33 (6%)	29 (5%)
Bradycardia	32 (6%)	30 (6%)
Shiver(s)	28 (5%)	30 (6%)
Urinary retention	28 (5%)	18 (3%)
Hypotension	27 (5%)	32 (6%)
Pruritus	27 (5%)	20 (4%)

The adverse experience profile seen with ZOFRAN ODT Orally Disintegrating Tablets was similar to that seen with ZOFRAN Tablets.

DRUG ABUSE AND DEPENDENCE: Animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.

OVERDOSAGE: There is no specific antidote for ondansetron overdose. Patients should be managed with appropriate supportive therapy. Individual intravenous doses as large as 145 mg and total daily intravenous doses as large as 252 mg have been inadvertently administered without significant adverse events. These doses are more than 10 times the recommended daily dose.

Hypotension (and faintness) occurred in a patient that took 48 mg of ZOFRAN Tablets. The events resolved completely.

DOSAGE AND ADMINISTRATION:

Instructions for Use/Handling ZOFRAN ODT Orally Disintegrating Tablets: Do not attempt to push ZOFRAN ODT Tablets through the foil backing. With dry hands, PEEL BACK the foil backing of one blister and GENTLY remove the tablet. IMMEDIATELY place the ZOFRAN ODT Tablet on top of the tongue where it will dissolve in seconds, then swallow with saliva. Administration with liquid is not necessary.

Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is one 8-mg ZOFRAN Tablet or one 8-mg ZOFRAN ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of ZOFRAN Oral Solution given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg ZOFRAN Tablet or one 8-mg ZOFRAN ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of ZOFRAN Oral Solution should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.

Pediatric Use: For patients 12 years of age and older, the dosage is the same as for adults. For patients 4 through 11 years of age, the dosage is one 4-mg ZOFRAN Tablet or one 4-mg ZOFRAN ODT Tablet or 5 mL (1 teaspoonful equivalent to 4 mg of ondansetron) of oral solution given three times a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. One 4-mg ZOFRAN Tablet or one 4-mg ZOFRAN ODT Tablet or 5 mL (1 teaspoonful equivalent to 4 mg of ondansetron) of ZOFRAN Oral Solution should be administered three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.

Use in the Elderly: The dosage is the same as for the general population.

Prevention of Nausea and Vomiting Associated With Radiotherapy, Either Total Body Irradiation, or Single High-Dose Fraction or Daily Fractions to the Abdomen: The recommended oral dosage is one 8-mg ZOFRAN Tablet or one 8-mg ZOFRAN ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of ZOFRAN Oral Solution given three times a day.

For total body irradiation, one 8-mg ZOFRAN Tablet or one 8-mg ZOFRAN ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of ZOFRAN Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.

For single high-dose fraction radiotherapy to the abdomen, one 8-mg ZOFRAN Tablet or one 8-mg ZOFRAN ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of ZOFRAN Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.

For daily fractionated radiotherapy to the abdomen, one 8-mg ZOFRAN Tablet or one 8-mg ZOFRAN ODT Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of ZOFRAN Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.

Pediatric Use: There is no experience with the use of ZOFRAN Tablets, ZOFRAN ODT Tablets, or ZOFRAN Oral Solution in the prevention of radiation-induced nausea and vomiting in children.

Use in the Elderly: The dosage recommendation is the same as for the general population.

Postoperative Nausea and Vomiting: The recommended dosage is 16 mg given as two 8-mg ZOFRAN Tablets or two 8-mg ZOFRAN ODT Tablets or 20 mL (4 teaspoonfuls equivalent to 16 mg of ondansetron) of ZOFRAN Oral Solution 1 hour before induction of anesthesia.

Pediatric Use: There is no experience with the use of ZOFRAN Tablets, ZOFRAN ODT Tablets, or ZOFRAN Oral Solution in the prevention of postoperative nausea and vomiting in children.

Use in the Elderly: The dosage is the same as for the general population.

Dosage Adjustment for Patients With Impaired Renal Function: No specific studies have been conducted in patients with renal insufficiency.

Dosage Adjustment for Patients With Impaired Hepatic Function: In patients with severe hepatic insufficiency, clearance is reduced, apparent volume of distribution is increased with a resultant increase in plasma half-life, and bioavailability approaches 100%. In such patients, a total daily dose of 8 mg should not be exceeded.

HOW SUPPLIED: ZOFRAN Tablets, 4 mg (ondansetron HCl dihydrate equivalent to 4 mg of ondansetron), are white, oval, film-coated tablets engraved with "Zofran" on one side and "4" on the other in daily unit dose packs of 3 tablets (NDC 0173-0446-04), bottles of 30 tablets (NDC 0173-0446-00), and unit dose packs of 100 tablets (NDC 0173-0446-02).

ZOFRAN Tablets, 8 mg (ondansetron HCl dihydrate equivalent to 8 mg of ondansetron), are yellow, oval, film-coated tablets engraved with "Zofran" on one side and "8" on the other in daily unit dose packs of 3 tablets (NDC 0173-0447-04), bottles of 30 tablets (NDC 0173-0447-00), and unit dose packs of 100 tablets (NDC 0173-0447-02).

Store between 2° and 30°C (36° and 86°F). Protect from light. Store blisters and bottles in cartons.

ZOFRAN ODT Orally Disintegrating Tablets, 4 mg (as 4 mg ondansetron base) are white, round and plano-convex tablets with no marking on either side in unit dose packs of 30 tablets (NDC 0173-0569-00).

ZOFRAN ODT Orally Disintegrating Tablets, 8 mg (as 8 mg ondansetron base) are white, round and plano-convex tablets with no marking on either side in unit dose packs of 30 tablets (NDC 0173-0570-00).

Store between 2° and 30°C (36° and 86°F).

ZOFRAN Oral Solution, a clear, colorless to light yellow liquid with a characteristic strawberry odor, contains 5 mg of ondansetron HCl dihydrate equivalent to 4 mg of ondansetron per 5 mL in amber glass bottles of 50 mL with child-resistant closures (NDC 0173-0489-00).

Store upright between 15° and 30°C (59° and 86°F). Protect from light. Store bottles upright in cartons.

GlaxoWellcome

Glaxo Wellcome Inc.

Research Triangle Park, NC 27709

ZOFRAN Tablets and Oral Solution:
Glaxo Wellcome Inc., Research Triangle Park, NC 27709

ZOFRAN ODT Orally Disintegrating Tablets:
Manufactured for Glaxo Wellcome Inc.
Research Triangle Park, NC 27709
by Scherer DDS
Blagrove, Swindon, Wilkshire, UK SN5 8RU

US Patent Nos. 4,695,578; 4,753,789; and 5,578,628

July 1998 RL-

Submission ~~dated~~ 7/31/98

Firm informed that this is DRAFT

NDA 20-781

FINAL PRINTED LABELING

ZOFRAN® ODT™
(ondansetron)
Orally Disintegrating Tablets

- Foil Blister Backing Material x 4 mg
- Carton x 30 x 4 mg
- Foil Blister Backing Material x 8 mg
- Carton x 30 x 8 mg
- Foil Blister Backing Material x 8 mg Sample
- Blistercard x 1 Sample
- Carton x 5 Blistercards x 1 Sample

NDA 20-781

FINAL PRINTED LABELING

ZOFRAN® ODT™
(ondansetron)
Orally Disintegrating Tablets

Foil Blister Backing Material x 4 mg



NDA 20-751
FINAL PRINTED LABELING
ZOFRAN® ODT™
(ondansetron)
Orally Disintegrating Tablets
Carton x 30 x 4 mg



NDA 20-781

FINAL PRINTED LABELING

ZOFRAN® ODT™
(ondansetron)
Orally Disintegrating Tablets

Foil Blister Backing Material x 8 mg



NDA 20-781
FINAL PRINTED LABELING
ZOFRAN® ODT™
(ondansetron)
Orally Disintegrating Tablets
Carton x 30 x 8 mg



NDA 20-781

FINAL PRINTED LABELING

ZOFRAN® ODT™
(ondansetron)
Orally Disintegrating Tablets

Foil Blister Backing Material x 8 mg Sample

FINAL PRINTED LABELING
ZOFRAN® ODT™
(ondansetron)
Orally Disintegrating Tablets
Blistercard x 1 Sample

Pull up perforated area and remove blister.



Wet Dry hands, peel printed backing completely off the blister. Do not push tablet through foil.



Gently remove tablet and immediately place on tongue to dissolve. Swallow with saliva.



NDC 0173-0570-00

Zofran® ODT™

(ondansetron)

Orally Disintegrating Tablets

8 mg

Each tablet contains 8 mg ondansetron base.

Store between 15° and 30°C (59° and 86°F)

Phenylketonurics: Contains phenylalanine.

Rx only

See package insert for Dosage and Administration

US Patent Nos. 4,695,578; 4,753,789; and 5,578,626

1 Tablet

GlaxoWellcome

Manufactured by Scherer DDS
Blagrove, Swindon, Wiltshire, UK SN5 8RU
for Glaxo Wellcome Inc.
Research Triangle Park, NC 27709
Made in England

410061 Rev. 7/98

Zofran® ODT™
(ondansetron)
Only Disintegrating Tablets
8 mg

Sample—Not for Sale

NDA 20-781

FINAL PRINTED LABELING

ZOFRAN® ODT™
(ondansetron)
Orally Disintegrating Tablets

Carton x 5 Blistercards x 1 Sample



8 mg

Each tablet contains 8 mg ondansetron base.
Store between 2° and 30°C (36° and 86°F).
Phenylketonurics: Contains phenylalanine.
Rx only
See package insert for Dosage and Administration.
US Patent Nos. 4,695,578; 4,753,789; and 5,578,628

GlaxoWellcome
Manufactured by Scherer DDS
Blagrove, Swindon, Wiltshire, UK SN5 8RU
for Glaxo Wellcome Inc.
Research Triangle Park, NC 27709
Made in England



Zofran® ODT
(ondansetron)
Orally Disintegrating Tablets
8 mg

5 Tablets
5 blisters/cards each
containing 1 tablet

Sample — Not for Sale

4100627

Zofran® ODT
(ondansetron)
Orally Disintegrating Tablets
8 mg

Sample — Not for Sale

4100627
Rev. 7/98